↓ Skip to main content

Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol

Overview of attention for article published in BMC Infectious Diseases, September 2018
Altmetric Badge

About this Attention Score

  • Above-average Attention Score compared to outputs of the same age (63rd percentile)
  • Good Attention Score compared to outputs of the same age and source (73rd percentile)

Mentioned by

twitter
8 X users
reddit
1 Redditor

Citations

dimensions_citation
34 Dimensions

Readers on

mendeley
249 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Impact of alcohol consumption on tuberculosis treatment outcomes: a prospective longitudinal cohort study protocol
Published in
BMC Infectious Diseases, September 2018
DOI 10.1186/s12879-018-3396-y
Pubmed ID
Authors

Bronwyn Myers, Tara C Bouton, Elizabeth J Ragan, Laura F White, Helen McIlleron, Danie Theron, Charles D H Parry, C Robert Horsburgh, Robin M Warren, Karen R Jacobson

Abstract

An estimated 10% of tuberculosis (TB) deaths are attributable to problematic alcohol use globally, however the causal pathways through which problem alcohol use has an impact on TB treatment outcome is not clear. This study aims to improve understanding of these mechanisms. Specifically, we aim to 1) assess whether poor TB treatment outcomes, measured as delayed time-to-culture conversion, are associated with problem alcohol use after controlling for non-adherence to TB pharmacotherapy; and 2) to determine whether pharmacokinetic (PK) changes in those with problem alcohol use are associated with delayed culture conversion, higher treatment failure/relapse rates or with increased toxicity. Our longitudinal, repeated measures, prospective cohort study aims to examine the associations between problem alcohol use and TB treatment outcomes and to evaluate the effect of alcohol on the PK and pharmacodynamics (PD) of TB drugs. We will recruit 438 microbiologically confirmed, pulmonary TB patients with evidence of rifampicin susceptibility in Worcester, South Africa with 200 HIV uninfected patients co-enrolled in the PK aim. Participants are followed for the six months of TB treatment and an additional 12 months thereafter, with sputum collected weekly for the first 12 weeks of treatment, alcohol consumption measures repeated monthly in concert with an alcohol biomarker (phosphatidylethanol) measurement at baseline, and in person directly observed therapy (DOT) using real-time mobile phone-based adherence monitoring. The primary outcome is based on time to culture conversion with the second objective to compare PK of first line TB therapy in those with and without problem alcohol use. Globally, an urgent need exists to identify modifiable drivers of poor TB treatment outcomes. There is a critical need for more effective TB treatment strategies for patients with a history of problem alcohol use. However, it is not known whether poor treatment outcomes in alcohol using patients are solely attributable to noncompliance. This study will attempt to answer this question and provide guidance for future TB intervention trials. Clinicaltrials.gov Registration Number: NCT02840877 . Registered on 19 July 2016.

X Demographics

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 249 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 249 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 36 14%
Student > Master 30 12%
Student > Bachelor 29 12%
Student > Ph. D. Student 20 8%
Student > Postgraduate 15 6%
Other 37 15%
Unknown 82 33%
Readers by discipline Count As %
Medicine and Dentistry 62 25%
Nursing and Health Professions 26 10%
Psychology 13 5%
Immunology and Microbiology 10 4%
Biochemistry, Genetics and Molecular Biology 6 2%
Other 44 18%
Unknown 88 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 01 April 2019.
All research outputs
#7,174,980
of 23,881,329 outputs
Outputs from BMC Infectious Diseases
#2,260
of 7,931 outputs
Outputs of similar age
#123,373
of 343,861 outputs
Outputs of similar age from BMC Infectious Diseases
#33
of 127 outputs
Altmetric has tracked 23,881,329 research outputs across all sources so far. This one has received more attention than most of these and is in the 69th percentile.
So far Altmetric has tracked 7,931 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.5. This one has gotten more attention than average, scoring higher than 71% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 343,861 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.
We're also able to compare this research output to 127 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 73% of its contemporaries.